Key result
Magnetic resonance spectroscopy of plasma showed a 7 Hz difference in mean line width for solid tumors versus controls, but hyperlipidemia acts as a major confounding variable.
Why the study?
Does magnetic resonance spectroscopy of plasma accurately distinguish patients with cancer from those with hyperlipidemia and healthy controls?
Observational (n=281)
Does magnetic resonance spectroscopy of plasma accurately distinguish patients with cancer from those with hyperlipidemia and healthy controls?
Hyperlipidemia acts as a significant confounding variable in the magnetic resonance plasma test for cancer, limiting its diagnostic specificity.
Answers are grounded in this paper and cite their sources.
Hyperlipidemia confounds plasma MRS line width for cancer detection; leaves open diagnostic specificity without lipid adjustment.
An increase in the plasma levels of apoprotein B-containing lipoproteins is the basis of the magnetic resonance (MR) test for cancer. The narrow MR line width reported by Fossel and co-workers to be associated with the presence of malignant disease is due to a relative increase of very low density lipoprotein. In contrast, the plasma from healthy controls, which has a much broader spectrum, has a higher proportion of high density lipoprotein. However, plasma from patients with hyperlipidemia unrelated to cancer also show narrow MR line widths and are therefore a confounding variable. We used magnetic resonance spectroscopy (MRS) to assess the plasma from 253 patients with a range of lipid related diseases and cancer, and 28 controls. A significant difference (p less than or equal to 0.0005) of 10 Hz exists between the mean line width of the controls and hyperlipidemics without malignant disease. However, in patients with solid tumours a difference of 7 Hz (p less than or equal to 0.0005) in the mean values is recorded although there is an overlap of 6 Hz compared with the controls. Moreover the MRS method was not found to distinguish patients with lymphomas from the control population. The index was not found to be related to patient age or tumour burden.
No takes yet. Share an insight, caveat, or question.
Holmes et al. (1988) conducted an observational in Cancer and hyperlipidemia (n=281). Magnetic resonance spectroscopy (MRS) of plasma vs. Healthy controls was evaluated on Mean MR line width (7 Hz difference (solid tumours vs controls), p=≤0.0005). Magnetic resonance spectroscopy of plasma showed a 7 Hz difference in mean line width for solid tumors versus controls, but hyperlipidemia acts as a major confounding variable.
Synapse has enriched 10 related papers. Consider them for comparative context: